Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,773 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04989985RecruitingPhase 2
SOX chemotherapy plus immunotherapy for junction stomach-esophagus cancer
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
Guangzhou, GuangdongAges 18–75 - NCT05062005RecruitingPhase 3
Tests two ways of treating locally advanced nasopharyngeal cancer
This phase 3 trial compares a standard treatment plan (CRT) versus a new approach (ICCRT) for people with locally advanced nasopharyngeal cancer, without spread to distant organs. It aims to see which plan works better and is safe for tumors in the head and neck area.
Guangzhou, GuangdongAges 18–65 - NCT04991948RecruitingPhase 1
Testing pembrolizumab after CYAD-101 plus FOLFOX in colon cancer
This early-phase study tests whether adding pembrolizumab after CYAD-101 and FOLFOX chemotherapy can help treat metastatic colon or rectal cancer. It is mainly looking for safety and signs of how well the treatment works in people whose cancer has not responded to prior therapy.
Jacksonville, FloridaAges 18 years+ - NCT05085171RecruitingPhase 3
Care plan to help reduce death risk in advanced HIV
This Phase 3 study tests an enhanced clinic care package for adults with advanced HIV to lower the risk of death. It may help by improving follow-up and treatment support for people who need closer care.
KampalaAges 18 years+ - NCT05300269RecruitingPhase 2
Test drug SHR-1701 with chemo and radiation for rectal cancer
This trial studies whether adding SHR-1701 to standard chemotherapy and long-course radiation can improve treatment for locally advanced rectal cancer that can be removed by surgery. It’s mainly for people who have not had prior rectal cancer treatment and who fit several health and cancer-spread requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05397769RecruitingPhase 2
Test envafolimab with chemoradiation for advanced nasopharyngeal cancer
This trial studies whether adding envafolimab (an immune medicine) to standard chemo and radiation works better for people with locally advanced, untreated nasopharyngeal cancer. It may help the immune system attack the cancer while treatment shrinks it.
Guangzhou, GuangdongAges 18–65 - NCT05406999RecruitingPhase 2
Intense hormone treatment before prostate surgery for high-risk cancer
This Phase 2 trial studies giving strong hormone-based treatment before prostate surgery to shrink and control high-risk, locally advanced prostate cancer. It may help improve surgical success and reduce cancer spread risk, but it requires careful health checks and prior-treatment limits.
Nanjing, JiangsuAges 18–80 - NCT05524090Recruiting
Program to prepare for surgery in locally advanced pancreatic cancer
This trial studies an “implementation program” to help patients with locally advanced pancreatic cancer get ready for the next steps after chemotherapy. It may help improve care planning and outcomes for people whose cancer has not grown after initial treatment.
Amsterdam, North HollandAges 18 years+ - NCT04263298RecruitingPhase 3
Fulvestrant or capecitabine after chemo for metastatic breast cancer
This Phase 3 trial compares two medicines—fulvestrant versus capecitabine—as “maintenance” treatment after your first chemo helps control metastatic breast cancer. It aims to see which one helps people live longer with better disease control.
Guangzhou, GuangdongAges 18–75 - NCT04192253RecruitingPhase 2
Carboplatin and paclitaxel before surgery for vulvar cancer
This trial tests giving chemotherapy (carboplatin and paclitaxel) before surgery for certain cases of squamous cell vulvar cancer. It may help shrink the tumor and make surgery more effective.
AmsterdamAges 18 years+ - NCT05620693Recruiting
Cell therapy study for NY-ESO-1–positive soft tissue cancer
This trial tests an engineered immune cell treatment (NY-ESO-1 TCR-T) for people with advanced soft tissue sarcoma that has returned or spread after standard treatment. It aims to treat cancer cells that show a specific marker (NY-ESO-1) in the tumor.
Shenzhen, GuangdongAges 18–70 - NCT05356039Recruiting
Study of surgery options and quality of life in pancreatic cancer
This study looks at people with borderline-resectable or locally advanced pancreatic cancer to see how treatment choices affect survival, quality of life, and whether tumors can be removed by surgery. It may help doctors better predict who can benefit from surgical approaches and what outcomes matter most to patients.
UmeåAges 18 years+ - NCT05725200RecruitingPhase 2
Personalized treatment plan for metastatic colon or rectal cancer
This Phase 2 trial tests an individualized treatment chosen from your tumor’s lab testing (genetic and RNA profile plus a drug-sensitivity test from your tumor cells). It may help by matching you to targeted anti-cancer drugs that are most likely to work for your specific cancer.
OsloAges 18 years+ - NCT05802394Recruiting
Using blood tests to track cancer after pancreatic treatment
This trial studies whether a blood test (ctDNA, a DNA signal from tumors) can help track how pancreatic cancer responds during planned conversion therapy. It may help doctors spot treatment response earlier and guide next steps.
BeijingAges 18 years+ - NCT05452213RecruitingPhase 4
Study patterns of ribociclib response and resistance in breast cancer
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
Erlangen, BavariaAges 18 years+ - NCT05833893RecruitingPhase 2
Selinexor plus COPL for newly diagnosed advanced NK/T lymphoma
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
Beijing, HaidianAges 14 years+ - NCT05655247Recruiting
Comparing two gum treatments for multiple exposed tooth roots
This trial compares two types of gum surgery to cover exposed tooth roots when you have multiple adjacent gum recessions. It aims to find which approach works best for root coverage and long-term gum health.
TarantoAges Any age - NCT05860868RecruitingPhase 3
Two versus three chemo treatments before radiation for nasopharyngeal cancer
This Phase 3 trial compares giving two cycles versus three cycles of chemotherapy before other treatment for locally advanced nasopharyngeal cancer. It may help find which schedule works best to control the cancer while managing side effects.
Guangzhou, Other (Non U.s.)Ages 18–65 - NCT05904964RecruitingPhase 3
Targeted drug for hormone-positive, HER2-low metastatic breast cancer
This Phase 3 trial tests disitamab vedotin (a targeted drug) in people with hormone receptor–positive, HER2-low metastatic breast cancer that can’t be cured with surgery or radiation. It aims to see whether the drug can control the cancer better than current standard care.
Guangzhou, GuangdongAges 18–70 - NCT05940441Recruiting
Low-dose capecitabine after throat cancer treatment
This study tests whether low-dose capecitabine given after standard treatment can lower the chance that locoregional (nearby) throat cancer returns. It is designed for adults with advanced hypopharyngeal (throat) cancer who have finished curative chemoradiation or surgery and follow-up therapy and show no active cancer on exam.
ShanghaiAges 18–65 - NCT05950087Recruiting
Blood tests after chemoradiotherapy for cervical cancer prognosis
This study looks at blood markers—tiny DNA from the blood (cfDNA) and minimal residual disease (MRD)—to better predict outcomes after standard chemoradiotherapy for locally advanced cervical cancer. It may help doctors identify who is more likely to do well and who may need closer follow-up or additional treatment planning.
Guiyang, GuizhouAges 18–75 - NCT05983107RecruitingPhase 2
Chidamide/Everolimus for advanced breast cancer
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
Beijing, Beijing MunicipalityAges 18–75 - NCT05378087Recruiting
Compare two ways to plan treatment for cervical cancer
This study compares two staging methods—using surgery results versus imaging tests—to help doctors plan treatment for locally advanced cervical cancer. It may improve how accurately the cancer is mapped, which could affect treatment choices and outcomes.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06043973RecruitingPhase 3
Almonertinib plus anlotinib for first-line advanced lung cancer
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
Jinan, ShandongAges 18–75
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,773 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.